Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Regeneron Pharmaceuticals Inc    REGN   US75886F1075

SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Regeneron: Sanofi Plans to Increase Stake to Over $500 Million of Stock

02/11/2013 | 10:44am US/Eastern
   By Melodie Warner 

Regeneron Pharmaceuticals Inc. (>> Regeneron Pharmaceuticals Inc) said Sanofi S.A. (SNY, SAN.FR) notified the biopharmaceutical company of its intent to boost its investment in the company and push its ownership of voting securities to more than $500 million.

Sanofi currently holds about 17% of Regeneron's shares outstanding, according to FactSet Research.

Regeneron said a December 2007 investor agreement bonds the French drug maker to certain standstill provisions, including an agreement not to acquire more than 30% of Regeneron's Class A stock and common stock outstanding.

Regeneron said these standstill provisions are in effect until the fifth anniversary of the expiration of a license and collaboration agreement between the companies.

Sanofi and Regeneron have worked together on experimental cancer drug Zaltrap, among other things.

Shares of Regeneron rose 5.6% to $175.13 in recent trading and have climbed 24% in the past three months.

Write to Melodie Warner at

Subscribe to WSJ:

Stocks mentioned in the article : Regeneron Pharmaceuticals Inc
React to this article
3d ago REGENERON PHARMACEUTICALS : Announces Presentation and Panel Discussion at the 3..
5d ago REGENERON PHARMACEUTICALS : "Methods for Treating Allergy and Enhancing Allergen..
7d ago REGENERON PHARMACEUTICALS : Have You Been Counted? Regeneron and Sanofi US Join ..
12/10 REGENERON PHARMACEUTICALS : EYLEA® aflibercept Injection Accepted for Priority R..
12/10 REGENERON PHARMACEUTICALS : Ablexis Announces Availability of the AlivaMab Mouse..
12/05 REGENERON PHARMACEUTICALS : Ablexis Announces Availability of the AlivaMab Mouse..
12/04 REGENERON PHARMACEUTICALS : Patent Issued for Methods of Producing Hybrid Antibo..
12/03 REGENERON PHARMACEUTICALS : and Sanofi Announce that Dupilumab Has Received FDA ..
12/01 REGENERON PHARMACEUTICALS : EYLEA® (aflibercept) Injection Accepted for Priority..
Duration : Period :
Regeneron Pharmaceuticals  Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes